Preliminary Results of the First-in-Human, Dose-Finding PROCLAIM-CX-072 Trial of the PD-L1 Probody Therapeutic as Monotherapy in Patients With Advanced Solid Tumors

**Background**

- PD-L1 is a cell-surface receptor expressed on cancer cells and immune cells.
- Targeted therapy for cancer involves blocking interactions between PD-L1 and PD-L2 on immune cells to stimulate the immune system.
- Probody therapeutics are designed to be activated specifically in relevant tissues.

**Objective**

- Investigate clinical activity and safety of CX-072 in patients with advanced solid tumors.

**Methods**

- **Study Design:** Phase 1, open-label, single-ascending dose evaluation with 2 expansion cohorts.
- **Patient Population:** Adults ≥18 years with advanced solid tumors and measurable disease.
- **Drug Administration:** CX-072 was administered intravenously every 2 weeks.
- **Endpoints:**
  - **Primary:** Safety and tolerability.
  - **Secondary:** Clinical activity and pharmacokinetics.

**Results**

- **Safety:**
  - 14 patients have been treated at doses of 0.03, 0.3, 1.0, and 3.0 mg/kg.
  - 3 patients experienced grade 3-4 adverse events, but none were treatment-related.

- **Pharmacokinetics:**
  - Median serum concentration of intact CX-072 was 31.1 nM at day 1.

- **Clinical Activity:**
  - Target lesions decreased from baseline in 6 of 10 patients (60%) at ≥3 mg/kg.

**Conclusion**

- CX-072 demonstrates promising clinical activity and a favorable safety profile in patients with advanced solid tumors.

**References**

2. Wolchok JD et al.

**Acknowledgments**

- The authors thank the patients and the institutions of the investigators for participation in the trial.
- Funding support from Genmab A/S and Protherics International.

**Contact Information**

- Genmab A/S, 5250 Herlev, Denmark; Protherics International, 827-211 Nashville, TN; Columbia University, New York, NY; University of Wisconsin Carbone Cancer Center, Madison, WI; University of California, Irvine, CA; and other institutions.

**Additional Information**

- For more information, visit the PROCLAIM website: www.PROCLAIMtrials.com.

**Interim Conclusions**

The interim results suggest that CX-072 has promising clinical activity and a favorable safety profile, supporting further investigation in advanced solid tumors.